However, in a randomized, double-blind, placebo-controlled clinical trial in patients with VLCAD or CPT2 deficiency, bezafibrate failed to improve cardiac function or whole-body fatty acid oxidation [37]. This evidence concerns the gene CPT2 and very long chain acyl-CoA dehydrogenase deficiency.